SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a notable pullback as Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 for weight loss, unavailable on HIMS's platform, intensifies competition in the telehealth weight management sector. This, coupled with a recent Bank of America downgrade citing potential margin pressure, has sparked a polarized community debate: many see the stock as "broken," while long-term investors highlight oversold conditions and strong fundamentals as a significant buying opportunity.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amidst extreme price plunges, largely driven by persistently warm winter forecasts and ample natural gas supplies. The community is expressing widespread despair over significant losses, with many desperately hoping for an "arctic blast" or "polar vortex" to reverse the devastating trend for this highly volatile, leveraged ETF, while others question its long-term viability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is actively trending following positive regulatory feedback that significantly de-risks its lead drug, sonelokimab, by allowing a Biologics License Application filing without additional trials. This pivotal development, coupled with recent analyst upgrades and upcoming investor events, has fueled extensive community speculation about a potential strategic acquisition, with many anticipating substantial upside from the biotech's de-risked asset.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with heightened anticipation for its J.P. Morgan Healthcare Conference presentation, where updates on Briumvi's robust market adoption and 2026 guidance are highly awaited. Community sentiment is also notably buoyed by recent competitor setbacks that underscore Briumvi's strong profile, leading to active discussions around potential strategic acquisitions and the influence of short positions.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as the market closely watches unfolding developments in Venezuela, with the US administration signaling that American oil companies could be heavily involved in revitalizing the nation's vast oil reserves. This potential for asset recovery and new investment is fueling bullish sentiment and discussions of significant upside. However, community conversations also highlight widespread concerns regarding market oversupply, political complexities, and the long-term feasibility of such ventures.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is generating significant buzz due to a special cash dividend, the strategic involvement of investor David Lazar, and high short interest fueling short squeeze speculation. The community is sharply divided, with many anticipating substantial upside while others warn of a pump-and-dump. Conversation is also driven by recent filings hinting at a strategic pivot towards blockchain or financial infrastructure, comparing NBY to other low-float, high-volatility plays.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited is trending due to recent news of a private placement and a significant acquisition, alongside the expiration of its IPO lock-up period. This low-float Hong Kong stock has ignited a fierce debate within the community, with many anticipating a short squeeze reminiscent of other volatile "China plays," while others warn of a rapid pump-and-dump scenario.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings (VWAV) is generating significant buzz following a series of strategic developments in its AI, defense, and drone technology sectors, including recent patent grants and acquisitions. The community is highly bullish, anticipating a major "parabolic" move or short squeeze driven by the stock's extremely low float and high institutional ownership, with many drawing comparisons to past high-growth stocks. Investors are also noting its "Strong Buy" rating from Nasdaq Dorsey Wright and successful pilot programs, signaling strong potential for commercialization and growth.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense community debate surrounding an ICE agent's fatal shooting in Minneapolis, with newly analyzed footage fueling polarizing arguments about justified force versus alleged government overreach. This contentious environment is further amplified by ongoing discussions about the release of "Epstein files" and President Trump's recent engagement with oil executives regarding Venezuela's energy sector. The stock remains highly sensitive to these significant political and social controversies, influencing investor sentiment and trading conversations.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund (UNG) is experiencing extreme volatility as natural gas prices react to conflicting short-term weather forecasts and a recent larger-than-expected storage draw, which still points to ample overall supply. Community discussion reveals a sharp division, with some investors buying dips on hopes of a polar vortex and growing demand from AI data centers, while others continue to short, citing persistent oversupply and the instrument's historical 'widow maker' volatility and perceived market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$sfix
Stitch Fix issued new fiscal 2026 guidance, projecting Q2 net revenue of $335M to $340M and full year net revenue of $1.32B to $1.35B, signaling confidence in a return to growth.
The company previously guided Q1 fiscal 2026 net revenue to $333M to $338M and full year net revenue of $1.28B to $1.33B, outlining a clearer recovery path for the next 12 months.
Stitch Fix launched Stitch Fix Vision, a generative AI powered style visualization tool that creates personalized, shoppable outfit imagery based on each client’s profile and real time trends.
The company completed a $30M share repurchase program, buying back 2,302,141 shares, or about 2.11% of shares under its January 6, 2022 authorization, returning capital to shareholders. https://finance.yahoo.com/news/recent-shifts-rewriting-turnaround-story-210704911.html

Joao Almeida

Stitch Fix's latest price target update keeps the fair value estimate anchored at $5.25 per share, even as assumptions around growth and risk are fine tuned. With the discount rate nudging lower and revenue growth expectations inching higher, analysts see a cautiously improving backdrop that could reshape how investors read the story from here.

Yahoo Finance

How Recent Shifts Are Rewriting the Turnaround Story for Stitch Fix

StockTwits for iOS

Stitch Fix Inc


Stitch Fix issued new fiscal 2026 guidance, projecting Q2 net revenue of $335M to $340M and full year net revenue of $1.32B to $1.35B, signaling confidence in a return to growth.
The company previously guided Q1 fiscal 2026 net revenue to $333M to $338M and full year net revenue of $1.28B to $1.33B, outlining a clearer recovery path for the next 12 months.
Stitch Fix launched Stitch Fix Vision, a generative AI powered style visualization tool that creates personalized, shoppable outfit imagery based on each client’s profile and real time trends.
The company completed a $30M share repurchase program, buying back 2,302,141 shares, or about 2.11% of shares under its January 6, 2022 authorization, returning capital to shareholders. 